Adrian L Harris

Summary

Affiliation: Imperial Cancer Research Fund
Country: UK

Publications

  1. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  2. ncbi Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
    Rebecca J Appelhoff
    Henry Wellcome Bldg of Genomic Medicine, Roosevelt Drive, Headington, Oxford, UK
    J Biol Chem 279:38458-65. 2004
  3. ncbi Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
    Juan Carlos Martinez
    CRUK Tumour Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 54:598-606. 2009
  4. ncbi Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Breast Cancer Res 9:R89. 2007
  5. ncbi Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK
    Breast Cancer Res Treat 111:453-9. 2008
  6. ncbi Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 27:227-34. 2009
  7. ncbi Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:550-8. 2007
  8. ncbi Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 67:11244-53. 2007
  9. ncbi Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer
    Daniele Generali
    Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:921-30. 2006
  10. ncbi Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells
    Laura S Harrington
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Microvasc Res 75:144-54. 2008

Detail Information

Publications119 found, 100 shown here

  1. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  2. ncbi Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
    Rebecca J Appelhoff
    Henry Wellcome Bldg of Genomic Medicine, Roosevelt Drive, Headington, Oxford, UK
    J Biol Chem 279:38458-65. 2004
    ....
  3. ncbi Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
    Juan Carlos Martinez
    CRUK Tumour Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 54:598-606. 2009
    ..Our aim was to pursue this by raising a monoclonal antibody to the internal domain of DLL4 and assess its distribution in normal and malignant tissues in comparison with antibodies against the external domain of DLL4...
  4. ncbi Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Breast Cancer Res 9:R89. 2007
    ..The present study investigates the role of FIH-1 in invasive breast carcinoma and its correlation with hypoxia...
  5. ncbi Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK
    Breast Cancer Res Treat 111:453-9. 2008
    ..FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERalpha, ERbeta or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism...
  6. ncbi Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 27:227-34. 2009
    ..We aimed to identify signaling pathways involved in the response and resistance to aromatase inhibitor therapy in patients with breast cancer...
  7. ncbi Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:550-8. 2007
    ..The HAI-2 predictive role was assessed in T(2-4) N(0-1) breast cancers (n = 177) enrolled in a neoadjuvant randomized trial comparing epirubicin versus epirubicin + tamoxifen...
  8. ncbi Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 67:11244-53. 2007
    ....
  9. ncbi Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer
    Daniele Generali
    Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:921-30. 2006
    ..Studies investigating the effects of pH on tamoxifen uptake and the effects of therapy with CA inhibitors are planned...
  10. ncbi Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells
    Laura S Harrington
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Microvasc Res 75:144-54. 2008
    ..The regulation of sVEGFR1 provides a novel mechanism for Dll4 signalling to regulate cells at distance, not just in adjacent cells...
  11. ncbi Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Circ Res 95:162-9. 2004
    ..This represents a novel mechanism of action for hydralazine and presents HIF as a potential target for treatment of ischemic disease...
  12. ncbi BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Clin Cancer Res 13:467-74. 2007
    ..Its perinecrotic localization within ductal carcinoma in situ (DCIS) suggests an involvement in neoplastic cellular adaptation to low oxygen tension. This study has investigated the role of BNIP3 in normal and neoplastic breast...
  13. ncbi Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 14:2673-80. 2008
    ..However, the effects of endocrine therapy with aromatase inhibitors on in vivo expression of this signaling cascade, and its relation to tumor response and patient outcome, is unknown...
  14. ncbi Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival
    Leticia Campo
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    J Pathol 205:585-91. 2005
    ..63) survival was observed in patients stratified by angiogenin expression. This study suggests that angiogenin may be important in breast cancer progression and that, through its relationship with ER, it may be a target for tamoxifen...
  15. ncbi The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth
    Jun Yang
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom
    Cancer Res 70:6456-66. 2010
    ..Our findings provide a biological rationale to support the therapeutic targeting of histone demethylases in breast cancer patients...
  16. ncbi Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
    Jonathan D Silk
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Clin Invest 114:1800-11. 2004
    ....
  17. ncbi Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion
    Naomi Robertson
    Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 64:6160-5. 2004
    ..Thus, CAIX plays an important role in the growth and survival of tumor cells under normoxia and hypoxia, making it a potential target for cancer therapy, but is not involved in invasion...
  18. ncbi Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia
    Alison H Banham
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    Prostate 67:1091-8. 2007
    ..This study investigated whether FOXP1 has a similar relationship to the androgen receptor (AR) in prostate cancer and how these factors relate to the presence of hypoxia...
  19. ncbi Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function
    Nilay S Patel
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, London United Kingdom
    Cancer Res 65:8690-7. 2005
    ..We conclude that an optimal window of the DLL4 expression is essential for tumor angiogenesis and that selective modulation of the DLL4 expression within human tumors may represent a potential novel antiangiogenic therapy...
  20. ncbi Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths
    Pawel Swietach
    Department of Physiology, Anatomy, and Genetics, Burdon Sanderson Cardiac Science Centre, Oxford, UK
    J Biol Chem 283:20473-83. 2008
    ..We suggest that pH(i) coordination may favor survival and growth of a tumor. By disrupting spatial pH(i) control, inhibition of CA9 activity may offer a novel strategy for the clinical treatment of CA9-associated tumors...
  21. ncbi A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines
    Tsung Wen Chong
    Cancer Research United Kingdom, Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Cancer Res 62:6924-7. 2002
    ..DFE potentially could be useful in cancer therapy by inducing apoptosis via NIP3 in conjunction with other non-HIF-related growth inhibitory pathways and blocking endothelial proliferation despite the presence of VEGF...
  22. ncbi The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib
    Manuela Milani
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
    Cancer Res 69:4415-23. 2009
    ....
  23. ncbi The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer
    Stuart C Winter
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer 107:757-66. 2006
    ..Anemia may contribute to hypoxia by reducing oxygen delivery, but it is not known whether this influences HIF-alpha expression in tumors...
  24. ncbi New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes
    Helen Sheldon
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 116:2385-94. 2010
    ..This reversal in phenotype appears to enhance vessel formation and is a new form of signaling for Notch ligands that expands their signaling potential beyond cell-cell contact...
  25. ncbi Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, Weatherall Institute ofMolecular Medicine, University of Oxford, Oxford, UK
    Am J Pathol 176:2019-28. 2010
    ..002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor...
  26. ncbi Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK
    Clin Cancer Res 12:5384-94. 2006
    ..CONCLUSIONS: AJM290 and AW464 are inhibitors of HIF-1alpha CAD transcription activity and DNA binding, but they also inhibit degradation of HIF, in contrast to other Trx inhibitors...
  27. ncbi Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase
    Howard R Mellor
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
    Biochem Pharmacol 79:1562-72. 2010
    ..This study provides new insight into the post-translational functional control of these Bcl-2 family members...
  28. ncbi DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo
    Ji Liang Li
    Molecular Oncology Laboratories, Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 71:6073-83. 2011
    ....
  29. ncbi Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia
    Heidi M Sowter
    Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Cancer Res 63:6130-4. 2003
    ..Remarkably, among a panel of hypoxia-inducible genes, responses were critically dependent on Hif-1 alpha but not Hif-2 alpha in both endothelial and breast cancer cells but critically dependent on Hif-2 alpha in renal carcinoma cells...
  30. ncbi Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 15:1046-51. 2009
    ....
  31. ncbi Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells
    Helen J Knowles
    Cancer Research United Kingdom Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS
    Cancer Res 63:1764-8. 2003
    ..These results indicate that both ascorbate and iron availability have major effects on HIF, and imply that the system is commonly regulated by limiting hydroxylase activity under normoxic tissue culture conditions...
  32. ncbi Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms
    Sarah A Lowndes
    Cancer Research UK Department of Medical Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
    Microvasc Res 77:314-26. 2009
    ..RNA interference to AQP1 inhibited endothelial proliferation and migration, confirming the role of AQP1 in endothelial cell function. Therefore regulation of AQP1 may represent an important action of copper chelation therapy...
  33. ncbi Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
    Stuart C Winter
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital
    Cancer Res 67:3441-9. 2007
    ..The work highlights the validity and potential of using data from analysis of in vitro stress pathways for deriving a biological metagene/gene signature in vivo...
  34. ncbi Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer
    Nilay S Patel
    Growth Factor Group, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 12:4836-44. 2006
    ..To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis...
  35. ncbi Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 24:5373-80. 2006
    ..To assess the clinical significance of tumor-infiltrating FOXP3-positive regulatory T cells (TR) in breast cancer patients with long-term follow-up...
  36. ncbi Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom
    J Immunol 175:8431-7. 2005
    ....
  37. ncbi Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis
    Alexandra Giatromanolaki
    Department of Pathology, Democritus University of Thrace, Medical School, PO Box 12, Alexandroupolis 68100, Greece, and John Radcliffe Hospital, Oxford, UK
    Gynecol Oncol 103:912-8. 2006
    ..In this study, the expression of LDH-5 was assessed in the normal and malignant endometrium. Its role in prognosis and tumor angiogenesis and hypoxia was also examined...
  38. ncbi Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 12:4562-8. 2006
    ....
  39. ncbi Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells
    Cassin Kimmel Williams
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 68:1889-95. 2008
    ..Thus, Dll4 may contribute to vascular differentiation and inhibition of the angiogenic response by regulating multiple receptor pathways...
  40. ncbi microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
    Francesca M Buffa
    Oncology Department, Weatherall Institute of Molecular Medicine, University of Oxford and Genomics Research, Wellcome Trust Centre for Human Genetics, Oxford, UK
    Cancer Res 71:5635-45. 2011
    ..Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets...
  41. ncbi Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade
    Heidi Michelle Sowter
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    J Pathol 201:573-80. 2003
    ..BNip3 was present in tumour-associated macrophages and in apocrine metaplastic lesions. Expression of NIX did not correlate with any of the parameters investigated...
  42. ncbi hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer
    Harriet E Gee
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Cancer 116:2148-58. 2010
    ..The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis...
  43. ncbi Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX3 9DS, UK
    Int J Cancer 113:259-66. 2005
    ....
  44. ncbi Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Cancer Res 66:2600-7. 2006
    ..These results indicate that physiologic changes in macrophage iron metabolism have an important effect on HIF hydroxylase pathways and suggest means by which the system could be manipulated for therapeutic benefit...
  45. ncbi The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours
    Helen Turley
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Pathol 203:808-13. 2004
    ..Its interrelationship with other hypoxically regulated molecules, such as the hypoxia-inducible factors or carbonic anhydrase IX, and differentiation of tumours now requires further investigation...
  46. ncbi Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells
    Kurosh Ameri
    Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 103:1876-82. 2004
    ..Thus, this study demonstrates a novel HIF-1alpha-independent anoxic mechanism that regulates ATF-4 induction at the protein stability level in tumor cells...
  47. ncbi The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer
    Howard R Mellor
    Growth Factor Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK
    Cancer Metastasis Rev 26:553-66. 2007
    ..However, the mechanism through which BNIP3 induces autophagy and the cellular consequences of this are yet to be established...
  48. ncbi Angiogenesis in bladder cancer--prognostic marker and target for future therapy
    Edward H Streeter
    Imperial Cancer Research Fund Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Surg Oncol 11:85-100. 2002
    ..Evidence for its role in bladder carcinogenesis, its usefulness as a marker of patient prognosis, and potential anti-angiogenic therapies for future development are discussed in this chapter...
  49. ncbi Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
    Mol Cancer Ther 5:2193-202. 2006
    ..Our cell-based approach and deconvolution of the inhibitory effect of DJ12 has identified a novel compound that targets the hypoxia pathway by inhibiting Hif-alpha-inducible transcription...
  50. ncbi Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Cancer Res 66:2749-56. 2006
    ..The use of anti-TfR mAbs and ascorbate in inhibiting both cell proliferation and HIF-1alpha and angiogenesis under normoxic conditions may be of therapeutic use...
  51. ncbi Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    J Cell Mol Med 14:18-29. 2010
    ..This review aims to discuss the clinical impact of translational work on hypoxia markers and to explore future directions for research in this area...
  52. ncbi Roles of tetrahydrobiopterin in promoting tumor angiogenesis
    Liye Chen
    Department of Clinical Pharmacology, University of Oxford, John Radcliffe Hospital, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Am J Pathol 177:2671-80. 2010
    ..Our findings suggest that BH4 synthesis may be a rational target for antiangiogenesis therapy for tumors...
  53. ncbi The role of hypoxia regulated microRNAs in cancer
    Robert McCormick
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Curr Top Microbiol Immunol 345:47-70. 2010
    ..miR-210 expression correlates with poor survival in cancer patients, and shows promise for future use as a tumour marker or therapeutic agent. The role of miR-210 and other HRMs in cancer biology is the subject of this review...
  54. ncbi Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas
    Stephen B Fox
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
    Clin Cancer Res 10:3521-7. 2004
    ..The FOXP1 gene, which maps to 3p14, shows common loss of heterozygosity in breast tumors and is a candidate tumor suppressor gene. However, its role in breast cancer is unknown...
  55. ncbi The potential of new tumor endothelium-specific markers for the development of antivascular therapy
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Cancer Cell 11:478-81. 2007
    ....
  56. ncbi Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion
    Pawel Swietach
    Department of Physiology, Anatomy and Genetics, Parks Road, Oxford, UK
    BJU Int 101:22-4. 2008
  57. ncbi Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target
    Christian Potter
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford, UK
    Cell Cycle 3:164-7. 2004
    ..As it is commonly expressed in tumours with the worst prognosis it is a potential target for therapy...
  58. ncbi Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Biochem Pharmacol 71:646-56. 2006
    ..This suggests a novel mechanism(s) mediating the clinical effects of pharmacological doses of niacin...
  59. ncbi MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU
    Elena Favaro
    Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    PLoS ONE 5:e10345. 2010
    ..Hypoxia in cancers results in the upregulation of hypoxia inducible factor 1 (HIF-1) and a microRNA, hsa-miR-210 (miR-210) which is associated with a poor prognosis...
  60. ncbi Hypoxia-inducible factors and hypoxic cell death in tumour physiology
    Andrea L Bacon
    Cancer Research UK, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Ann Med 36:530-9. 2004
    ..Understanding the mechanisms by which HIF-1 induces cell death and the manner in which the tumour cell can overcome such signals, is critical for our understanding of cancer progression and the development of effective therapeutics...
  61. ncbi Targeting vascular endothelial growth factor in renal cell carcinoma
    Nilay S Patel
    Churchill Hospital, Oxford, UK
    Tumour Biol 30:292-9. 2009
    ....
  62. ncbi The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway
    Russell D Leek
    Growth Factor Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 65:4147-52. 2005
    ..These results indicate that the enhancing effect of HIF-1 in three-dimensional tumor growth is a balance of both reduced proliferation and enhanced survival, the latter being proportionally greater...
  63. ncbi Macrophage infiltration and angiogenesis in human malignancy
    Helen Knowles
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, UK
    Novartis Found Symp 256:189-200; discussion 200-4, 259-69. 2004
    ....
  64. ncbi Histological quantitation of tumour angiogenesis
    Stephen B Fox
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    APMIS 112:413-30. 2004
    ..Gene arrays may be able to provide an angiogenesis profile. Continued study into the processes involved in generating a tumour blood supply is likely to identify new markers that may be more accurate measures...
  65. ncbi Notch signaling from tumor cells: a new mechanism of angiogenesis
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Cell 8:1-3. 2005
    ..Selective interruption of Notch signaling within tumors may provide an antiangiogenic strategy...
  66. ncbi Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
    Ji Liang Li
    Cancer Research UK Molecular Oncology Department, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Front Biosci 14:3094-110. 2009
    ..Thus, targeting the DLL4/Notch pathway, though still at an early stage, may lead to exciting new therapies for clinical application...
  67. ncbi Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion
    Adam Jones
    Imperial Cancer Research Fund, University of Oxford Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    J Urol 167:1482-6. 2002
    ....
  68. ncbi c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism
    Ulrike E Knies-Bamforth
    Molecular Oncology Laboratory, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 64:6563-70. 2004
    ..Blocking VEGF signaling in vivo significantly reduced dermal angiogenesis, demonstrating the importance of VEGF as a mediating factor for the c-Myc-induced angiogenic phenotype...
  69. ncbi Role of hypoxia-inducible factor-1alpha as a cancer therapy target
    Shalini Patiar
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:S61-75. 2006
    ..Several novel small molecule inhibitors of HIF-1 have been identified and are moving towards clinical trials, but none of these are specific for HIF-1. Further work is ongoing to identify more selective HIF-1 inhibitors...
  70. ncbi Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Trends Mol Med 13:389-95. 2007
    ..Altogether, these molecules constitute a new category of pro-angiogenic yet anticancer agents and offer an exciting alternative to previously described vascular targeting molecules...
  71. ncbi The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis
    Emma Hormbrey
    Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, UK
    Clin Cancer Res 9:4332-9. 2003
    ..This has relevance for design of antiangiogenic therapy trials, highlighting the need for individually tailored treatment with biologically targeted interventions...
  72. ncbi NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
    Ian F Hermans
    Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5140-7. 2003
    ..Thus, iNKT cells exert a significant influence on the efficacy of immune responses to soluble Ag by modulating DC function...
  73. ncbi Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials
    Wen Shi
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, UK
    J Mammary Gland Biol Neoplasia 11:41-52. 2006
    ..A variety of strategies for blocking Notch signaling, in particular gamma-secretase inhibition, are discussed as potential therapies for breast cancer and tumor angiogenesis...
  74. ncbi Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation
    Kevin J Turner
    Imperial Cancer Research Fund Molecular Oncology Laboratory and Angiogenesis Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Cancer Res 62:2957-61. 2002
    ..These results suggest that activation of the HIF pathway is functionally important in CC-RCC development and might provide a new therapeutic target...
  75. ncbi Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Angiogenesis 11:41-51. 2008
    ....
  76. ncbi Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer
    Cory S M Williams
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    J Pathol 200:195-206. 2003
    ....
  77. ncbi Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases
    Jun Yang
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Ann N Y Acad Sci 1177:185-97. 2009
    ..This provides a new mechanism for regulation of the response to hypoxia...
  78. ncbi Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data
    Marialena Trivella
    Cancer Research UK NHS Centre for Statistics in Medicine, Oxford, UK
    Lancet Oncol 8:488-99. 2007
    ..We aimed to collect individual patient data to assess microvessel-density counts (ie, a measure of angiogenesis) as a prognostic factor in non-small-cell lung carcinoma...
  79. ncbi The unfolded protein response and integrated stress response to anoxia
    Tomasz Rzymski
    Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:2537-40. 2007
    ..Therefore, targeting additional components of anoxic pathways, besides the hypoxia-inducible response, may be effective for future anticancer therapies...
  80. ncbi Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2
    Veronica A Carroll
    Molecular Oncology Laboratory, Cancer Research UK, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Arterioscler Thromb Vasc Biol 25:736-41. 2005
    ..In addition, we identify the kringle 2 domain of tPA as a novel target for antiangiogenic therapy...
  81. ncbi Inclusion of vasculature-related variables in the Dukes staging system of colon cancer
    Michael I Koukourakis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece, and Department of Pathology, John Radcliffe Hospital, UK
    Clin Cancer Res 11:8653-60. 2005
    ..Improvement of the Dukes stage predictive accuracy is necessary to better assign patients for adjuvant therapies, especially nowadays when antiangiogenic agents are being incorporated in the clinical practice...
  82. ncbi Hypoxia-regulated differentiation: let's step it up a Notch
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Trends Mol Med 12:141-3. 2006
    ..The identification of this crosstalk between pathways that are often deregulated in cancer is groundbreaking and opens up new areas for cancer research...
  83. ncbi Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients
    Michael I Koukourakis
    Department of Radiotherapy, Democritus University of Thrace, Alexandroupolis 68100, Greece
    Cancer Res 63:5376-80. 2003
    ....
  84. ncbi Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis
    Alexandra Giatromanolaki
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece
    Arthritis Res Ther 5:R193-201. 2003
    ..The activation of the HIF-alpha pathway occurs in both RA and OA, although for unrelated reasons...
  85. ncbi Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin
    Alexandra Giatromanolaki
    Departments of Pathology, Dermatology and Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis, Greece
    Melanoma Res 13:493-501. 2003
    ..HIF2alpha, VEGF and, to a lesser extent, VD are important prognostic factors in these cutaneous tumours...
  86. ncbi DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer
    Alexandra Giatromanolaki
    Departments of Pathology and Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece
    J Pathol 200:222-8. 2003
    ..It is suggested that loss of DEC1 expression is an early event in the development of lung cancer, while DEC1 gene expression occurs in a subset of tumours and parallels the overexpression of other hypoxia-regulated proteins...
  87. ncbi Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway
    John R Griffiths
    CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry and Immunology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Cancer Res 62:688-95. 2002
    ..They suggest potential biochemical targets that may be modified by therapy blocking HIF-1 function...
  88. ncbi The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography
    David R Collingridge
    Cancer Research UK Positron Emission Tomography Oncology Group, Department of Cancer Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London W12 0NN
    Cancer Res 62:5912-9. 2002
    ..These studies support further development of [(124)I]-SHPP-VG76e as a radiotracer for measuring tumor levels of VEGF in humans...
  89. ncbi Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes
    Peter Birner
    Institute of Clinical Pathology, University of Vienna, Austria
    Brain Pathol 13:133-43. 2003
    ..Our findings denote for the first time distinct angiogenic subtypes of human glioblastoma which may prove relevant for anti-angiogenic therapy approaches...
  90. ncbi GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding
    Rachel E Airley
    School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United Kingdom
    Int J Cancer 104:85-91. 2003
    ..009). Thus, our study has shown that HIF-1 regulated genes have potential for future use as predictors of the malignant changes mediated by hypoxia, and warrant further investigation as indicators of response to cancer therapy...
  91. ncbi HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron
    Stefano J Mandriota
    Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, United Kingdom
    Cancer Cell 1:459-68. 2002
    ..In proximal tubules these were almost entirely unicellular, whereas multicellular foci were almost exclusively seen in the distal nephron...
  92. ncbi Drug inhibition of angiogenesis
    Srinivasan Madhusudan
    Cancer Research UK, Medical Oncology Unit, University of Oxford, The Churchill, Oxford Radcliffe Hospitals, OX3 7LJ, Oxford, United Kingdom
    Curr Opin Pharmacol 2:403-14. 2002
    ..A concerted international effort by cancer researchers and the pharmaceutical industry will help to further develop this novel treatment strategy for cancer...
  93. ncbi Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer
    Michael I Koukourakis
    Department of Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis, Greece
    Int J Radiat Oncol Biol Phys 53:1192-202. 2002
    ..Their putative role as markers of clinically relevant hypoxia and, therefore, as predictors of response to chemoradiotherapy is herein examined...
  94. ncbi Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival
    Edwin P Hui
    Departments of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Clin Cancer Res 8:2595-604. 2002
    ..Targeting the hypoxia pathway may be useful in the treatment of NPC...
  95. ncbi Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas
    Efthimios Sivridis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece
    J Pathol 196:416-22. 2002
    ..TP is not an effective contributor to the angiogenic process, but is associated with aggressive histological features. The two factors, when co-expressed, play a co-operative role in the induction of angiogenesis...
  96. ncbi Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer
    Russell D Leek
    Imperial Cancer Research Fund Tumor Pathology Unit, University of Oxford Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU [R. D. L, K. L. T, F. P, H. T, L. C, K. C. G
    Cancer Res 62:1326-9. 2002
    ..Thus, combined blockade of pathways and careful assessment of these pathways in trials are necessary...
  97. ncbi Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia
    Margaret J Currie
    Pathology Department, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    J Pathol 198:502-10. 2002
    ..These data suggest that it is endothelial induction of Ang-2 in tumours that regulates vessel stability and supports targeting Tie2 as an effective novel anti-angiogenic therapy in clear cell RCCs...
  98. ncbi Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer
    Nigel J P Beasley
    Oxford Centre for Head and Neck Oncology, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom
    Cancer Res 62:1315-20. 2002
    ..017), but no obvious correlation with intratumoral lymphatics. Our results provide new evidence that proliferating lymphatics can occur in human cancers and may in some cases contribute to lymph node metastasis...
  99. ncbi Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma
    Efthimios Sivridis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece
    Cancer 95:1055-63. 2002
    ....
  100. ncbi Angiogenesis in endocrine tumors
    Helen E Turner
    Department of Endocrinology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Endocr Rev 24:600-32. 2003
    ..An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment...
  101. ncbi Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1
    Kaye J Williams
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK
    Radiother Oncol 75:89-98. 2005
    ..Further, the results from the cell mixing experiments uncouple the growth promoting effects of HIF-1 and the underlying mechanism by which HIF-1 may increase radiation resistance in solid tumours...